Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion

Quoin Pharmaceuticals, Ltd.

Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.
Net loss of $3.8M for Q1 2025, versus $2.3M in Q1 2024.
QRX003 showed reversal of clinical benefits upon discontinuation, confirming mechanism of action.
Patent applications filed for topical rapamycin and novel QRX003 formulations, extending IP to 2045.
FDA-cleared whole-body QRX003 study at Northwestern University for 8-12 Netherton patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.